Know Cancer

forgot password

Phase I Study of Soluble LAG-3 (IMP321) and Gemcitabine in Patients With Advanced Pancreas Cancer

Phase 1
18 Years
Not Enrolling
Pancreatic Neoplasms

Thank you

Trial Information

Phase I Study of Soluble LAG-3 (IMP321) and Gemcitabine in Patients With Advanced Pancreas Cancer

This is a phase I, single center, open label, non-randomized, dose-escalation phase I study
performed in the ambulatory setting in patients receiving first line chemotherapy for
unresectable pancreas cancer with gemcitabine weekly and the investigational agent IMP321.
IMP321 will be given at D2 and D16 of a 4-week cycle, for a period of 6 months. The
hypothesis of this study is that IMP321 is safe for human administration. Additionally we
hypothesize that IMP321 elicits an immunomodulatory effect that is therapeutic in the
treatment of pancreas cancer.

Primary Objectives

- To evaluate the safety and tolerability of repeated IMP321 subcutaneous injections in
patients being treated with gemcitabine for advanced pancreas cancer.

- To determine any dose limiting toxicities of IMP321 in patients being treated with
gemcitabine for advanced pancreas cancer.

Secondary Objectives

- To describe the pharmacokinetics of the last IMP321 subcutaneous injection compared to
the first one, in a limited number of patients.

- To determine the pharmacodynamics of IMP321 therapy by:

- Quantify peripheral blood Treg (CD4+CD25+FoxP3+ T cells) in pancreatic cancer patients
before and during treatment with IMP321 by flow cytometry.

- Evaluate the B- and T-cell responses to the pancreatic cancer-expressed antigen,
mesothelin, by testing for antibodies and T-cell response by ELISpot.

- To evaluate the clinical response and time to disease progression with computed
tomography examinations at two month intervals (current standard of care in
gemcitabine-treated patients).

Inclusion Criteria:

- Patient must have a newly diagnosed, histologically or cytologically confirmed
diagnosis of pancreatic adenocarcinoma (primary tumor or metastasis). The
histological slides or blocks must be available for review.

- Patient must have advanced disease (characterized by metastasis or locally advanced
disease), or unable to undergo surgical treatment due to extent of disease or
pre-existing health conditions precluding surgical treatment.

- Measurable or evaluable disease: RECIST Criteria will be used to assess and survey
extent of disease

- Patients must be ≥ 18 years old.

- Performance Status: Karnofsky Performance Status (KPS) ≥ 70

- Life Expectancy > 12 weeks.

- No previous history of chemotherapy for pancreas cancer in the metastatic setting
prior to the start of protocol treatment.

- Patients must have recovered from uncontrolled, intercurrent illness including, but
not limited to, ongoing or active infection, symptomatic congestive heart failure,
unstable angina pectoris or cardiac arrhythmia.

- Patients must have adequate bone marrow function defined as an absolute neutrophil
count >1,500/mm3, platelet count >100,000/mm3 and hemoglobin >10 g/dl.

- Patients must have adequate renal function defined as serum creatinine ≤ 2.0 mg/dl or
creatinine clearance ≥ 60 ml/min/1.73m2 for patients with creatinine levels above 2.0

- Patients must have adequate hepatic function with total bilirubin ≤ 1.5 times the
institutional normal value and AST ≤ 2 times the institutional normal value.

- Patient must have no prior or current active autoimmune disease requiring management
with immunosuppression. This includes inflammatory bowel disease, systemic
vasculitis, scleroderma, psoriasis, hemolytic anemia, immune-mediated
thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjogren's
syndrome, sarcoidosis or other rheumatologic disease. Asthma and chronic obstructive
pulmonary disease that does not require daily systemic corticosteroids is acceptable.

- The patient with previous history of malignancy is eligible for this study only if
the patient meets the following criteria for cancer survivor:

- (i) patient has undergone potentially curative therapy for all prior

- (ii) patient has been considered disease free for at least 5 years.

- For all sexually active patients, the use of adequate barrier contraception (hormonal
or barrier method of birth control) will be required during therapy, prior to study
entry and for the duration of study participation. Patients must agree to refrain
from becoming pregnant 2 years after beginning treatment with IMP321. Non-pregnant
status will be determined in all women of childbearing potential.

- After being informed of the treatment involved, patients must give written consent.
The patient should not have any serious medical or psychiatric illness that would
prevent either the giving of informed consent or the receipt of treatment.

Exclusion Criteria:

- Patient is currently receiving other investigational agents.

- Pregnant and nursing women patients are not eligible.

- Patients known to be HIV (patient self-report) positive are ineligible because of the
potential inability to modulate immune responses.

- Patients with a QTc of >460 msec.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To evaluate the safety and tolerability of repeated IMP321 subcutaneous injections in patients being treated with gemcitabine for advanced pancreas cancer.

Outcome Time Frame:

6 months

Safety Issue:


Principal Investigator

William G. Hawkins, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Washington Univerisity


United States: Food and Drug Administration

Study ID:




Start Date:

February 2009

Completion Date:

September 2012

Related Keywords:

  • Pancreatic Neoplasms
  • LAG-3 and gemcitabine treatment for advanced pancreas cancer
  • Neoplasms
  • Pancreatic Neoplasms



Washington University St. Louis, Missouri  63110